Multiple Myeloma: From Molecular Insights to Clinical Treatments
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 May 2026 | Viewed by 3
Special Issue Editor
Interests: hemopoietic stem cell; transplantation; autologous; allogeneic; haploidentical; graft versus tumor; graft versus host; consolidation therapy; maintenance therapy
Special Issue Information
Dear Colleagues,
The last 25 years may be rightfully called a quarter of a century of steady advancements in myeloma therapy. The “calm waters” of alkylator-based and steroid-heavy myeloma therapies were disturbed by the serendipitous discovery of thalidomide, and a new era of bench-to-bedside novel therapies got underway. The identification of a possible novel therapeutic target, a myeloma “Achilles heel,” was usually followed by the development of drugs that target it. Proteasome inhibitors, new IMIDs as cereblon modulators, anti-CD38 antibodies, BCMA-targeted ADCs, bispecific antibodies, and CAR-T cells are notable examples of the success of this approach.
In this Special Issue of Cancers, our goal is to provide a publication avenue for novel therapeutic approaches that follow this development path. Basic science, early clinical, and advanced clinical observations related to novel therapeutic agents are welcome for publication.
As myeloma-treating physicians, although the progress has been tremendous, we are keenly aware of unmet medical needs in myeloma treatment, and I sincerely hope that this Special Issue will help to close some of our knowledge gaps that still exist in current myeloma therapy. In this Special Issue, original research articles and reviews are all welcome.
I look forward to receiving your contributions.
Dr. Mikala Gabor
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- novel therapy
- bispecific
- CelMod
- CAR-T
- CAR-NK
- ADC
- CD38
- BCMA
- GPRC5D
- FcRH5
- transplantation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
